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Rapid adaptation drives invasion 
of airway donor microbiota 
by Pseudomonas after lung 
transplantation
M. Beaume1, T. Köhler1, G. Greub2,3, O. Manuel3,4, J-D. Aubert4,5, L. Baerlocher6, L. Farinelli6, 
A. Buckling7 , C. van Delden1 & the Swiss Transplant Cohort Study†
In cystic fibrosis (CF) patients, chronic airway infection by Pseudomonas leads to progressive lung 
destruction ultimately requiring lung transplantation (LT). Following LT, CF-adapted Pseudomonas 
strains, potentially originating from the sinuses, may seed the allograft leading to infections and 
reduced allograft survival. We investigated whether CF-adapted Pseudomonas populations invade the 
donor microbiota and adapt to the non-CF allograft. We collected sequential Pseudomonas isolates and 
airway samples from a CF-lung transplant recipient during two years, and followed the dynamics of the 
microbiota and Pseudomonas populations. We show that Pseudomonas invaded the host microbiota 
within three days post-LT, in association with a reduction in richness and diversity. A dominant mucoid 
and hypermutator mutL lineage was replaced after 11 days by non-mucoid strains. Despite antibiotic 
therapy, Pseudomonas dominated the allograft microbiota until day 95. We observed positive selection 
of pre-LT variants and the appearance of novel mutations. Phenotypic adaptation resulted in increased 
biofilm formation and swimming motility capacities. Pseudomonas was replaced after 95 days by a 
microbiota dominated by Actinobacillus. In conclusion, mucoid Pseudomonas adapted to the CF-lung 
remained able to invade the allograft. Selection of both pre-existing non-mucoid subpopulations and of 
novel phenotypic traits suggests rapid adaptation of Pseudomonas to the non-CF allograft.
Lung transplantation (LT) is recognized as the ultimate therapeutic intervention for cystic fibrosis (CF) patients 
with end-stage lung disease. Unfortunately, allograft infections and development of chronic rejection lead to loss of 
graft function in about 50% of patients at five years1. CF lung-recipients suffer from chronic pre-transplant infec-
tions with microorganisms including Staphylococcus aureus, Burkholderia cepacia, and Pseudomonas aeruginosa, 
the latter predominating in adults2. P. aeruginosa outcompetes other bacteria and remarkably adapts to the par-
ticular CF-airway microenvironment by accumulating mutations over years3. Whereas lung transplantation 
removes the major infectious site, Pseudomonas potentially residing in the recipient’s sinuses may seed the 
allograft4,5. The success of Pseudomonas in colonizing the allograft airways depends on antibiotic treatments, the 
host response hampered by immunosuppressive therapies and initial mucosal damage6, as well as inter-species 
competition. Despite this challenging situation, allograft airway colonization by Pseudomonas is frequent7.
Little is known to date about the microbiota of lung transplant recipients. It remains unclear whether par-
ticular pre-LT infections/colonization are associated with poor post-LT outcomes. Several studies demonstrated 
that CF-patients infected by P. aeruginosa had more post-LT respiratory infections than non-infected non-CF 
patients8,9. However, no significant difference in survival was reported. In addition, CF-patients infected with 
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pan-resistant microorganisms seem to have a reduced post-LT survival compared to patients infected with 
antibiotic-susceptible bacteria10. Other studies using culture-independent methods suggested differences between 
the microbiota of CF as compared to non-CF lung transplant recipients11 and healthy control patients12, mainly 
due to the ubiquity and dominance of Pseudomonas in CF-patients11.
To explain the successful allograft colonization by Pseudomonas we can envisage that the CF-adapted strains 
also survive in a non-CF allograft environment, or that Pseudomonas can adapt rapidly to the novel physiological 
and microbiological conditions prevailing in the allograft. Here, we attempt to distinguish between these hypoth-
eses by following the population dynamics, and by defining the real-time phenotypic and molecular evolution of 
Pseudomonas post-transplant. Specifically, we investigated longitudinal airway samples from both intermediate 
(conductive zone) and distal (respiratory zone) sites in a CF-lung transplant recipient chronically infected by 
P. aeruginosa before transplantation and transiently thereafter, while simultaneously characterizing changes in 
the co-colonizing microbiota. We find compelling evidence for major changes in the allograft microbiota and for 
rapid adaptation of Pseudomonas population to the allograft.
Results
Pseudomonas colonized the conductive allograft airways in the first days after LT. We studied 
the dynamics of total microbial communities of the allograft conductive and respiratory airways using 16 S rRNA 
gene sequencing of one pre-LT and six successive post-LT bronchial aspirates (0, 3, 11, 25, 95, 200 days), as well as 
of three post-LT bronchoalveolar lavages (25, 200 and 718 days)(Table 1). Bacterial community diversity and rich-
ness were determined by the Shannon-Weaver and the S indexes respectively13. Pseudomonas and Staphylococcus 
genera dominated in the bronchial aspirate (BA) before LT (day − 1) with elevated bacterial counts, and low 
Shannon and S indexes (Fig. 1c,d and e). The BA at the time of LT (day 0) reflected the donor airway microbial flora 
with a completely different distribution (Fig. 1c). Both indexes were elevated indicating a high microbial diver-
sity and richness, typically characterizing healthy lungs12 (Fig. 1e). This sample already contained P. aeruginosa, 
detectable both by qPCR and bacterial culture. At D3 post-LT, abundance of the Pseudomonas genus had already 
increased in a BA (Fig. 1c and d) and the pre-LT distribution was restored 11 days after LT, with de novo col-
onization of the graft airways by Pseudomonas and Staphylococcus genera (Fig. 1c). This shift went along with 
an increase of total bacterial and P. aeruginosa loads, despite targeted antibiotherapy (Fig. 1d). Shannon and 
S values of the BA dropped close to pre-LT levels, indicating a decrease of bacterial diversity and richness in 
the conductive airways of the transplant (Fig. 1e). The predominance of these two pathogens was maintained 
for one month after LT (day 25) in both BA and BAL, although Pseudomonas and total bacterial abundance 
decreased 10 fold. Bacterial culture data were consistent with taxonomic analyses of the microbial communities, 
showing a high abundance of Pseudomonas between day three and 25 post-LT (Fig. 1b). At day 95, the situation 
had inversed and several members of the commensal flora such as Actinobacillus and Bordetella had efficiently 
outgrown Pseudomonas and Staphylococcus in the BA (Fig. 1c,d). After six months (day 200), Pseudomonas rep-
resented less than 0.17% of all bacterial taxons, a result confirmed by qPCR (Fig. 1d). At this point, the BA was 
mainly colonized by Actinobacillus and Neisseria genera, with low Shannon and S values. This contrasted with a 
high microbial diversity and richness in a concomitant BAL (Fig. 1e). Despite aggressive antibiotic treatments the 
absolute abundance of total bacteria did not vary drastically after transplantation, showing only a 10-fold decline 
between day 25 and 200. Note that colonization by Mycobacterium disappeared after day 95 in BA and day 200 in 
BAL (Table S1).
Gender Female
CFTR genotype Δ F508 homozygous
Medical history Bilateral lung transplantation Pancreatic failure with diabetes
Age at LT (years) 32
Years post-LT (01/12/2014) 3.25
Extubation (days post-LT) 4
Forced expiratory volume (% of the predicted value)
 1 month post-LT 70
 3 months post-LT 82
 6 months post-LT 80
 1 year post-LT 78
 2 years post-LT 83
 3 years post-LT 90
Time-points of sampling (days post-LT)*
 BA (n= 8) −1; 0; 3; 5; 11; 25; 95; 200
 BAL (n= 3) 25; 200; 718
Table 1.  Summary of CF-subject characteristics and samples. *Samples from which P. aeruginosa was 
isolated are indicated in bold. Samples submitted to 16 S rRNA sequencing and taxonomic analysis are 
underlined.
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Population dynamics and evolution of Pseudomonas isolates after LT. To determine if pre-LT 
and post-LT isolates had the same genotypes, we performed both Random Amplification of Polymorphic DNA 
(RAPD) and a more discriminative analysis using the Clondiag array14. Genotypic analysis confirmed that the 
same unique genotype was recovered before and after LT from the conductive airways (Fig. S1). We investigated 
whether the passage from the CF-environment (sinuses or other recipient body sites) to the non-CF-environment 
(airways of the donor allograft) resulted in rapid adaptive evolution by first sequencing the genomes of two 
pre-LT Pseudomonas isolates (Z(− 1)A and Z(− 1)B), as well as the last available post-LT isolate at day 95 (Z95B). 
A total of 74 mutations were identified by comparing the genomes of these three isogenic strains (Fig. 2a, 
Tables S2 and S3). The strain isolated at day 95 showed 15 mutations (11 SNPs, three deletions and one insertion) 
Figure 1. Evolution of the microbial airway composition after LT. Shown are the sequential analysis 
of bronchial aspirates (BA) and bronchoalveolar lavages (BAL) collected pre- and post-LT. (a) Timing of 
antimicrobial and immunosuppressing therapies. (b) Bacterial cultures over time. Bacterial load (number of 
cells/mL) is represented as following: red square, > 105; orange square, 103–104; yellow square, < 103; white 
square, positive culture; crossed square, not determined. (c) Taxonomic analysis, cutoff set > 1%. (d) Absolute 
bacterial abundance determined by performing qPCR on gDNA extracted from native airway samples. qPCR 
detection limit established at 103 rspL copy number/mL of sample. (e) Microbial diversity and richness.
Figure 2. Genome comparison between two pre-LT and one late post-LT isolate. (a) Venn diagram 
summarizing the number of mutations identified in each genome. (b) Description of the 15 mutations detected 
in the genome of the final post-LT isolate Z95B.
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that were absent in both pre-LT isolates (Fig. 2a). Ten of these were non-synonymous, and three were in inter-
genic regions, suggesting positive selection acted on at least some of these mutations, although genetic hitchhik-
ing may explain the increase in frequency of others (Fig. 2b). The mutations occurred in genes coding for proteins 
belonging to several functional categories: regulators (37%), cell metabolism (18%), cell cycle control (18%), 
hypothetical proteins (18%), transport and secretion (9%). Z95B shared eight mutations with Z(− 1)B, but none 
with Z(−1)A. We further quantified by deep sequencing the relative amount of 13 alleles mutated in strain Z95B 
within the native bronchial aspirates. This allowed us to follow both the emergence and the evolution of each 
mutation within the whole Pseudomonas population over a 3 months period (Fig. 3). We identified two distinct 
sub-populations. The first one, already present pre-LT, decreased from 60 to 20% at the time of transplantation, 
and then rapidly increased after day three in the allograft airways to reach 90–100% of the total P. aeruginosa pop-
ulation at day 95 (blue lines in Fig. 3a). The second sub-population, absent before and at the time of LT, remained 
undetectable until day 25 post-LT and reached about 40 to 60% at day 95 (brown-orange lines in Fig. 3a). These 
differences in frequency through time were all significant with a sequencing coverage comprised between 5’541 
and 513’882 reads per sample per target. Of notice the Z(−1)A genome contained a non-synonymous SNP in the 
mutL gene, encoding a DNA mismatch repair protein. Mutations in mutL have been associated with the hyper-
mutator phenotype showing a high prevalence in chronic respiratory infections15. This variant of the mutL gene 
initially increased and then disappeared at day 11 post-LT (Fig. 3a).
We further explored the post-LT evolutionary dynamics of mutations by characterizing specific genotypes and 
their phenotypes. We performed capillary sequencing on PCR products amplified from gDNA of ten isolates col-
lected between the day before transplantation (D−1) and D95 post-LT. We focused on non-synonymous muta-
tions absent in the two ancestor isolates Z(−1)A and B, but present in Z95B (gidA, hxcS, ftsY, PADK2–14410, 
PA4949, phoP, phoQ, PA1550, PA4288), as well as on mutations present in only one of the two ancestor genomes 
(mutL, dctQ, wspF, sucC, PA1419) (Fig. 3b). We were able to identify two independent lineages. Lineage A was 
Figure 3. In patient evolution of Pseudomonas genome variants after LT. (a) Relative abundance of mutated 
variants in the whole Pseudomonas population. Thirteen genes were amplified by PCR and amplicons were 
submitted to deep sequencing. Mutations previously identified in the Z95B genome were searched in the total 
pool of sequencing reads. The amount of wild-type and mutated versions of the gene are expressed as the 
percentage of mutated alleles in the total population for each gene. (b) Evolutionary history of Pseudomonas 
isolates and populations following LT. The vertical arrays show the status (wild-type or mutated) of each gene 
in strains isolated from bronchial aspirates. These data analyzed concomitantly to those obtained for the total 
population (panel A) allows to reconstruct the evolution of the isolates, and to determine their respective 
percentage of variants in the total Pseudomonas community. The status of the hypothetical intermediate 
genomes (deduced) and those of the most recent common ancestors (MRCA) were inferred from all data taken 
together. ex = extubation.
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characterized by a mucoid phenotype, probably due to a mutation in the algU promoter, and by mutations in 
wspF and dctQ. Isolates Z(−1)A, Z0, Z5A and Z11A seemed all to be descendants of a common ancestor carrying 
the wspF and dctQ mutations. Isolate Z11A probably derived directly from this ancestor, whereas isolate Z(−1)
A accumulated an additional mutation in mutL leading to a second sub-lineage including Z0 and Z5A. Lineage 
A reached about 40% of the total Pseudomonas population at day 11, but then disappeared at day 25. Lineage B 
was characterized by a non-mucoid phenotype and a mutation in ORF PA1419. This lineage represented 10% of 
the population at the time of transplantation, but was dominant after day 11 (Fig. 3b). It further split into two 
sub-lineages: the first one, represented by isolate Z(−1)B was not retrieved at a later time point. It carried a muta-
tion in sucC, and was unable to grow on succinate (Fig. 4a), a main carbon source of Pseudomonas. The second 
sub-lineage, harboring mutations in gidA, hxcS, ftsY, PADK2-14410 and PA4288, increased in proportion and 
represented 90% of the population at day 25. Three months post-LT, a new variant characterized by additional 
mutations in phoP, phoQ, PA1550 and PA4288 emerged from this sub-lineage. Deep sequencing data demon-
strated that two subpopulations, derived from lineage B, co-existed with similar proportions three months after 
LT, suggesting a positive selection for gidA, hxcS, ftsY, PADK2-14410, and PA4949 mutations.
Phenotypic analysis of post-LT isolates showed a progressive increase in biofilm formation capacity both in 
mucoid and non-mucoid lineages (Fig. 4b). In contrast, we observed the appearance of swimming motility16 
only in the last isolate (Z95B) of the non-mucoid lineage B (D95, Fig. 4b). This isolate also showed increased 
growth capacity in LB, M9 succinate and M9 citrate media (Fig. 4a). All isolates were susceptible to tobramycin. 
Imipenem and amikacin resistant isolates appeared in the mucoid lineage A at day 5, whereas non-mucoid iso-
lates were already resistant to these antibiotics before LT. Despite early colistin treatment, we observed resistance 
to colistin only at day 95 in the non-mucoid lineage B (Fig. 4a and Table S4).
Discussion
It has previously been unclear whether: i) colonization of the lung allograft by CF-adapted populations of 
Pseudomonas occurs because the allograft does not represent a particularly novel environment hence the pop-
ulations are already well adapted, or ii) the allograft represents a new environment (both in terms of recipient 
physiological and immunological status, and donor lung physiology and microbiota) to which Pseudomonas 
must adapt. We observed that, despite aggressive antimicrobial therapy and the preexisting donor microbial flora, 
Pseudomonas rapidly colonized the allograft after lung transplantation, in association with a drastic reduction of 
both microbial richness and diversity. Colonization was associated with rapid adaptive evolution of Pseudomonas, 
resulting from selection of a pre-existing sub-population and de novo mutations that emerged later during allo-
graft colonization. Although we cannot exclude that some mutations hitchhiked along with those under selection, 
Figure 4. Phenotypic analysis of ten P. aeruginosa strains isolated from sequential airway samples.  
(a) *indicate the antibiotic resistance (R) or susceptibility (S) phenotypes according to EUCAST breakpoints 
(minimal inhibitory concentrations are provided in Table S4). (b) Biofilms were stained with crystal violet after 
24 hours of static growth. Optical densities were measured at 590 nm. Biofilm formation of the reference strain 
PAO1 is shown for comparison. Error bars showed standard deviations; statistical significance was calculated by 
an unpaired t-test. Swimming phenotype was evaluated after 22 h of growth at 37 °C in LB 0.2% agar.
www.nature.com/scientificreports/
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the very low proportion of synonymous mutations and the large population size rules out genetic drift as a major 
driver of evolution.
What were the likely phenotypic consequences of the selected mutations, and why did they confer fitness ben-
efits or costs? We speculate that the sucC mutation was not detected post-LT, since it potentially prevented growth 
on succinate. Mucoid isolates and hypermutators (mutL-mutants) were both highly prevalent in the CF-lung 
environment15,17, and these isolates were probably the first to seed into the allograft from the CF-host environ-
ment. However, both phenotypes disappeared after day 11. We speculate that these CF-associated phenotypes 
were not required for persistence of Pseudomonas in its new environment. It has been hypothesised that the 
mucoid phenotype could protect Pseudomonas against host inflammatory defense mechanisms18. Maintenance 
of a mucoid phenotype might therefore not be favored by the post-transplant immunosuppressive therapy. In CF 
patients, P. aeruginosa isolates commonly acquire mutations in AlgU and MucA leading to overproduction of alg-
inate (mucoid phenotype), associated with a decline in lung function19. Several studies showed that alginate elicits 
opsonic antibody production and thus has strong immunogenic properties20,21. Mucoid isolates might have been 
counter-selected because of their high immunogenicity or because of environmental conditions22. Interestingly, 
the Pseudomonas biomass decreased along with the disappearance of the mucoid lineage.
Seven of the mutations were present at relatively high frequencies prior to LT but increased to almost 100% 
after three months. Mutations in gidA were shown to have important phenotypic effects: deletion of gidA reduced 
the virulence of several Gram-negative bacteria23, and was associated with down-regulation of rhl quorum-sensing 
in P. aeruginosa24. The advantage of some of the mutations that aroused de novo in the allograft environment 
is more obvious: phoP and phoQ mutations could be associated with colistin-resistance25,26, as well as reduced 
cytotoxicity27. Indeed, deletion of phoQ is one the most frequent mutational events linked to colistin resistance28. 
Interestingly previous work showed significantly impaired competitiveness of phoQ-mutants in a chronic rat lung 
infection model29. Selection of these mutations after LT clearly suggests that adaptation can occur in the graft.
We also observed a progressive increase of biofilm formation in the two lineages. This phenotype seems there-
fore particularly important initially for successful allograft colonization. The biofilm mode of growth is involved 
in persistence and antibiotic resistance30. The fact that biofilm formation increased independently in two different 
lineages during colonization suggests that genetic drift is unlikely to be responsible for this phenotype. At 95 days, 
increased swimming motility appeared as a de novo-acquired phenotype. Swimming motility and biofilm forma-
tion often oppose one another; our results suggest that both are not mutually exclusive. It is striking that swim-
ming motility appeared when the Pseudomonas biomass was significantly declining. One could postulate that it 
represents a bacterial survival strategy enabling bacteria to reach nutritionally more favorable niches, although 
hitchhiking with other traits may also be possible.
On the day of transplantation, the allograft microbiota was characterized by a high richness and diversity 
probably reflecting a healthy donor organ. However, within eleven days Pseudomonas and Staphylococcus invaded 
the graft and established a completely different microbiota similar to the pre-LT composition. This observation 
agrees with previous reports showing reduced richness and diversity following LT11,12. Interestingly, the microbial 
communities shifted again three months post-LT with a dominance of Actinobacillus. In parallel, Pseudomonas 
abundance declined, and diversity as well as richness increased in the lower airway samples. The difference 
between BA and BAL samples at day 200 could reflect the heterogeneity inside the lungs.
Based on our data, we can only speculate why the « healthy » microbiota finally replaced the predominance of 
the initially successful Pseudomonas predominating in both conductive and respiratory airways during the first 
months post-LT. Several factors might have influenced this outcome, but we suggest that Actinobacillus might 
have outcompeted Pseudomonas following the end of the imipenem therapy. Of importance, all Pseudomonas 
lineages were resistant to the various antibiotics used (including imipenem). One appealing hypothesis is that 
broad-spectrum antibiotherapy misbalanced the competition between the donor microbiota and Pseudomonas 
in favor of the latter. One other explanation is that systemic antibiotics were responsible for the major decrease of 
bacterial richness and diversity at day 11, without any involvement of P. aeruginosa.
It is possible that the observed changes in the Pseudomonas population occurred independently of lung trans-
plantation, hence the population did not adapt to the allograft at all. However, we believe this to be doubtful. 
While recent work has shown rapid turnover of P. aeruginosa genotypes in CF patients over a matter of months, 
these changes are the result of fluctuations in haplotypes31,32 and are not directional changes as observed here. 
Also, as suggested by some recent work33, the genotypic and phenotypic evolution observed in the isolates har-
vested from the allograft could have occurred initially in another recipient compartment. However, this seems 
unlikely to us given that all other recipient compartments, including the sinuses, remain a CF-environment con-
tinuously favouring a mucoid phenotype. Therefore, the disappearance of a mucoid phenotype in the allograft 
after day 11 post-LT suggests adaptation to the non-CF allograft microenvironment. Potentially whole genome 
sequencing, paired to deep-sequencing of the entire Pseudomonas population used in the present study detected 
adaptation to the non-CF allograft missed in other studies by specific-gene capillary sequencing, which does not 
offer the same analysis depth.
To our knowledge this study is the first to describe in detail the dynamics of P. aeruginosa adaptation during 
allograft colonization, due to the difficulty to obtain longitudinal clinical samples from lung transplant recipients.
In conclusion, our study shows that despite aggressive antibiotic therapy, colonization of the allograft by 
Pseudomonas occurred already in the first days after LT. This was associated with rapid adaptive evolution of 
the population and major changes in the pre-existing allograft microbiota. However, these rapid initial inva-
sion and adaptation did not allow long-term persistence of Pseudomonas post-LT in this patient after 95 days. 
Broad-spectrum antibiotics might have favoured Pseudomonas, which competed with the donor microflora. 
Although limited to a single patient our results clearly show that rapid adaptation to the novel environment may 
explain the successful colonisation of the lung allograft by Pseudomonas. Future studies, including larger numbers 
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of patients, will be crucial to understand the subtle interplay between invading Pseudomonas and donor microbi-
ota, to develop novel strategies preventing acute and chronic allograft infections.
Methods
Patient Characteristics. A 32 year-old CF female patient chronically infected by P. aeruginosa received a 
bilateral lung transplant for end-stage lung disease in 2011 (Table 1). As 95% of solid organ transplant recipients 
in Switzerland, she was included in the Swiss Transplant Cohort Study (STCS)34. Clinical data reported in the 
STCS database included culture-based microbiology assessments, antibiotic and immunosuppressive treatments, 
as well as the clinical status of the patient. We collected eight bronchial aspirates (BA) and three bronchoalveolar 
lavages (BAL) before, at the time of LT, and at various time points thereafter during two years (Table 1). The total 
clinical follow-up was 3.25 years. Due to pre-transplant colonization by Mycobacterium abscessus the patient was 
treated for a prolonged period with a combination of imipenem, linezolid, tigecycline and moxifloxacin (Fig. 1a).
Collection of native airway samples, DNA extraction and isolation of Pseudomonas. Sequential 
bronchial aspirates (BA) and bronchoalveolar lavages (BAL) were collected during routine surveillance bron-
choscopies. BA consisted of respiratory secretions aspirated below the bronchial suture, and represent heteroge-
neous sampling from both lungs at the level of the conductive airways. One BA sample was collected six hours 
post-transplantation and was labeled D0. BAL fluid was obtained by aspiration following instillation of > 100 ml 
of NaCl 0.9% through the bronchoscope wedged in a subsegmental bronchus, thus representing a more homog-
enous sample from a distal respiratory zone. One mL aliquots of native BA and BAL samples were frozen imme-
diately after sampling at − 80 °C. Pseudomonas strains were isolated from BA samples by the routine diagnostic 
microbiology laboratory of the university hospital of Lausanne. Total genomic DNA (gDNA) was extracted from 
native samples after chemical and mechanical lysis, using the DNeasy kit (QIAGEN) according to the manufac-
turer’s instructions.
Microbial community analysis. The V4-V6 regions of the 16 S rRNA gene were amplified by PCR (primer 
sequences in Table S5) and sequenced using an Illumina MiSeq platform (Fasteris SA, Switzerland). Filtered 
reads were mapped onto the GreenGenes database35 and were assigned to specific genus level lineages. Sample 
richness and diversity were calculated using the Shannon and S indexes respectively, with the VEGAN package 
with normalized data sets.
Quantitative real-time PCR (qPCR). qPCR was performed as previously described36. DNA was amplified 
using the SYBR Green Quantitect Kit (QIAGEN) with 0.6 μ M of 16 S rRNA or rpsL primers (Table S5). Gene copy 
numbers per mL of sample were determined comparing the obtained cycle threshold (Ct) to a standard curve 
performed with gDNA of P. aeruginosa reference strain PA14.
Genome analysis of clinical isolates. Genotyping. P. aeruginosa genotyping was performed by random 
amplification of polymorphic DNA (RAPD) using primer 208 as previously described37. Strains were further 
genotyped using the P. aeruginosa Clondiag kit14.
PCR for capillary sequencing or digestions. PCR was performed on bacterial lysates. Presence of muta-
tions was determined by sequencing or digestion of the purified PCR products (Table S6).
Whole-genome and deep sequencing. Genomic DNA was prepared from P. aeruginosa isolates using 
the DNeasy Blood and Tissue kit (QIAGEN). Multiplex PCRs of genes carrying mutated alleles were performed 
on gDNA of native airway samples. The Illumina HiSeq 2500 platform (Fasteris SA, Switzerland) was used for 
all sequencing processes. Assembly, mapping, variant calling and allelic counting are described in the online 
supplement.
Phenotypic assays. Microtiter dish biofilm. Bacteria were grown in M63 medium supplemented with 0.2% 
glucose, 2 mM MgSO4 and 0.05% Casamino acids in a 24-well polystyrene microtiter dish (Costar) at 30 °C under 
static conditions. Staining was performed as previously described38 and absorbance was measured at 590 nm.
Swimming motility. Bacteria were inoculated by toothpick into a 0.2% LB agar plate and incubated at 37 °C dur-
ing 22 h. Experiments were performed in duplicate.
Growth measurements. Cultures and pellets were prepared as described for the biofilm assay. LB medium or M9 
medium containing 2 mM MgSO4 and supplemented with 20 mM succinate or 25 mM citrate were inoculated 
with bacterial suspensions (final OD600= 0.2). Experiments were performed in duplicate.
Minimal inhibitory concentrations (MIC). MIC were determined as previously described39.
Nucleotide sequence accession. 16 S rRNA gene sequence files were deposited in EMBL-ENA under the 
accession number PRJEB13210, whole genome sequence files under the number PRJEB14598 and deep sequenc-
ing on the P. aeruginosa population under the number PRJEB14611 (Supplementary Table S7).
Additional details on the material and methods are provided in the supplementary information.
Ethical statement. Authorization to use all clinical samples for research purposes were obtained from the 
local ethical committee of the University Hospitals of Geneva (authorization CER 07–301), and the patient pro-
vided her written informed consent. All methods and experimental protocols were carried out in accordance with 
the approved guidelines.
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